Ondansétron Accord (Ondansetron)

Ondansetron, the active ingredient in Ondansétron Accord, is a 5-HT3 receptor antagonist presented as a 4 mg tablet for oral use. It helps prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery in adult and paediatric patients. GNH USA supplies Ondansétron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansétron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is employed across several therapeutic pathways to control nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: helps maintain patient comfort during and after treatment. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑associated nausea (hyperemesis gravidarum): used when other measures are insufficient, under specialist supervision. - Anticipatory nausea: lessens nausea that develops before chemotherapy cycles in patients with prior experience.

Side‑effect profiles reflect the drug’s pharmacology and patient variability.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel slowing. - Diarrhoea: transient loose stools. - Fatigue: general tiredness. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - QT‑interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Neuroleptic malignant‑like reactions: extremely uncommon but serious.

When prescribing Ondansétron Accord, clinicians should consider several safety aspects.

- Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte disturbances. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before initiation. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome. - Pregnancy and lactation: use only if clearly indicated after risk‑benefit assessment. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgement. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic agents (e.g., quinidine, amiodarone): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, tramadol): monitor for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower ondansetron exposure. - Diuretics causing electrolyte loss: watch for additive QT‑prolongation risk.